Comparison of Pharmacokinetics and Biodistribution of 10-Deacetylbaccatin III after Oral Administration as Pure Compound or in Taxus chinensis Extract: A Pilot Study

 

 Buy Article Permissions and Reprints

Abstract

Taxanes are a class of bioactive compounds isolated from the Taxus species. 10-Deacetylbaccatin III is one of the popular taxane compounds with antitumor activity, but the pharmacokinetic profile of this compound remains elusive. Previously, we prepared the taxane fractions from the twigs and leaves of Taxus chinensis var. mairei containing 20.4 % 10-deacetylbaccatin III. This study aimed to investigate the pharmacokinetics of 10-deacetylbaccatin III and biodistribution, and explore the potential changes when it was administered in the form of taxane extracts. A simple, sensitive, and reliable liquid chromatography-tandem mass spectrometry method was developed and validated for the quantitative determination of 10-deacetylbaccatin III in biosamples. The results showed that 10-deacetylbaccatin III, after oral dosing, displayed a quick absorption into the blood and distribution into major organs. Oral administration of 10-deacetylbaccatin III in the form of taxane mixtures led to a 16-fold increase in the systemic exposure of pure 10-deacetylbaccatin III, with the AUC_0-U in the plasma increasing from 25.75 ± 11.34 to 231.36 ± 70.12 µg h/L (p < 0.0001). Moreover, the concentrations of 10-deacetylbaccatin III in major tissues were significantly enhanced when given in taxane extracts. These findings revealed pharmacokinetic interactions in the taxane components from T. chinensis var. mairei, which contributed to an enhanced systemic exposure of pharmacologically active taxanes.

^* These two authors contributed equally to this work.

• References

• 1 DallʼAcqua S. Natural products as antimitotic agents. Curr Top Med Chem 2014; 14: 2272-2285
  CrossrefPubMedGoogle Scholar
• 2 Dumontet C, Jordan MA. Microtubule-binding agents: a dynamic field of cancer therapeutics. Nat Rev Drug Discov 2010; 9: 790-803
  CrossrefPubMedGoogle Scholar
• 3 Tsai AC, Wang CY, Liou JP, Pai HC, Hsiao CJ, Chang JY, Wang JC, Teng CM, Pan SL. Orally active microtubule-targeting agent, MPT0B271, for the treatment of human non-small cell lung cancer, alone and in combination with erlotinib. Cell Death Dis 2014; 5: e1162
  CrossrefPubMedGoogle Scholar
• 4 Jing YR, Zhou W, Li WL, Zhao LX, Wang YF. The synthesis of novel taxoids for oral administration. Bioorg Med Chem 2014; 22: 194-203
  CrossrefPubMedGoogle Scholar
• 5 Georgopoulou K, Smirlis D, Bisti S, Xingi E, Skaltsounis L, Soteriadou K. In vitro activity of 10-deacetylbaccatin III against Leishmania donovani promastigotes and intracellular amastigotes. Planta Med 2007; 73: 1081-1088
  Article in Thieme ConnectPubMedGoogle Scholar
• 6 Sreekanth D, Syed A, Sarkar S, Sarkar D, Santhakumari B, Ahmad A, Khan I. Production, purification and characterization of taxol and 10DAB III from a new endophytic fungus Gliocladium sp. isolated from the Indian yew tree, Taxus baccata . J Microbiol Biotechnol 2009; 19: 1342-1347
  PubMedGoogle Scholar
• 7 Krawczyk E, Luczak M, Kniotek M, Nowaczyk M. Cytotoxic, antiviral (in-vitro and in-vivo), immunomodulatory activity and influence on mitotic divisions of three taxol derivatives: 10-deacetyl-baccatin III, methyl (N-benzoyl-(2′R,3′S)-3′-phenylisoserinate) and N-benzoyl-(2′R,3′S)-3′-phenylisoserine. J Pharm Pharmacol 2005; 57: 791-797
  CrossrefPubMedGoogle Scholar
• 8 Han F, Kang LZ, Zeng XL, Ye ZW, Guo LQ, Lin JF. Bioproduction of baccatin III, an advanced precursor of paclitaxol, with transgenic Flammulina velutipes expressing the 10-deacetylbaccatin III-10-O-acetyl transferase gene. J Sci Food Agric 2014; 94: 2376-2383
  CrossrefPubMedGoogle Scholar
• 9 Frapolli R, Marangon E, Zaffaroni M, Colombo T, Falcioni C, Bagnati R, Simone M, DʼIncalci M, Manzotti C, Fontana G, Morazzoni P, Zucchetti M. Pharmacokinetics and metabolism in mice of IDN 5390 (13-(N-Boc-3-i-butylisoserinoyl)-C-7,8-seco-10-deacetylbaccatin III), a new oral c-seco-taxane derivative with antiangiogenic property effective on paclitaxel-resistant tumors. Drug Metab Dispos 2006; 34: 2028-2035
  CrossrefPubMedGoogle Scholar
• 10 Nicoletti MI, Colombo T, Rossi C, Monardo C, Stura S, Zucchetti M, Riva A, Morazzoni P, Donati MB, Bombardelli E, DʼIncalci M, Giavazzi R. IDN5109, a taxane with oral bioavailability and potent antitumor activity. Cancer Res 2000; 60: 842-846
  PubMedGoogle Scholar
• 11 Nicolaou KC, Valiulin RA. Synthesis and biological evaluation of new paclitaxel analogs and discovery of potent antitumor agents. Org Biomol Chem 2013; 11: 4154-4163
  CrossrefPubMedGoogle Scholar
• 12 Pepe A, Sun L, Zanardi I, Wu X, Ferlini C, Fontana G, Bombardelli E, Ojima I. Novel C-seco-taxoids possessing high potency against paclitaxel-resistant cancer cell lines overexpressing class III beta-tubulin. Bioorg Med Chem Lett 2009; 19: 3300-3304
  CrossrefPubMedGoogle Scholar
• 13 Ferlini C, Ojima I, Distefano M, Gallo D, Riva A, Morazzoni P, Bombardelli E, Mancuso S, Scambia G. Second generation taxanes: from the natural framework to the challenge of drug resistance. Curr Med Chem Anticancer Agents 2003; 3: 133-138
  CrossrefPubMedGoogle Scholar
• 14 Fu Y, Li S, Zu Y, Yang G, Yang Z, Luo M, Jiang S, Wink M, Efferth T. Medicinal chemistry of paclitaxel and its analogues. Curr Med Chem 2009; 16: 3966-3985
  CrossrefPubMedGoogle Scholar
• 15 Liu B, Gou X, Bai X, Hou X, Li D, Zhong G, Jin J, Huang M. Simultaneous determination of seven taxoids in rat plasma by UPLC-MS/MS and pharmacokinetic study after oral administration of Taxus yunnanensis extracts. J Pharm Biomed Anal 2015; 107: 346-354
  CrossrefPubMedGoogle Scholar
• 16 Li H, Wang S, Zhang B, Xie Y, Wang J, Yang Q, Cao W, Hu J, Duan L. Influence of co-administered danshensu on pharmacokinetic fate and tissue distribution of paeonol in rats. Planta Med 2012; 78: 135-140
  Article in Thieme ConnectPubMedGoogle Scholar
• 17 Yang M, Yang X, An J, Xiao W, Wang Z, Huang W, Yang Z, Li F. Comparative pharmacokinetic profiles of tectorigenin in rat plasma by UPLC-MS/MS after oral administration of Iris tectorum Maxim extract and pure tectoridin. J Pharm Biomed Anal 2015; 114: 34-41
  CrossrefPubMedGoogle Scholar
• 18 Liu M, Wang Q, Liu F, Cheng X, Wu X, Wang H, Wu M, Ma Y, Wang G, Hao H. UDP-glucuronosyltransferase 1 A compromises intracellular accumulation and anti-cancer effect of tanshinone IIA in human colon cancer cells. PLoS One 2013; 8: e79172
  CrossrefPubMedGoogle Scholar
• 19 Liu Z, Zheng X, Lv J, Zhou X, Wang Q, Wen X, Liu H, Jiang J, Wang L. Pharmacokinetic synergy from the taxane extract of Taxus chinensis improves the bioavailability of paclitaxel. Phytomedicine 2015; 22: 573-578
  CrossrefPubMedGoogle Scholar
• 20 Jin J, Cai D, Bi H, Zhong G, Zeng H, Gu L, Huang Z, Huang M. Comparative pharmacokinetics of paclitaxel after oral administration of Taxus yunnanensis extract and pure paclitaxel to rats. Fitoterapia 2013; 90: 1-9
  CrossrefPubMedGoogle Scholar
• 21 Hendrikx JJ, Lagas JS, Wagenaar E, Rosing H, Schellens JH, Beijnen JH, Schinkel AH. Oral co-administration of elacridar and ritonavir enhances plasma levels of oral paclitaxel and docetaxel without affecting relative brain accumulation. Br J Cancer 2014; 110: 2669-2676
  CrossrefPubMedGoogle Scholar
• 22 Hendrikx JJ, Lagas JS, Rosing H, Schellens JH, Beijnen JH, Schinkel AH. P-glycoprotein and cytochrome P450 3 A act together in restricting the oral bioavailability of paclitaxel. Int J Cancer 2013; 132: 2439-2447
  CrossrefPubMedGoogle Scholar
• 23 Wang S, Hu Y, Tan W, Wu X, Chen R, Cao J, Chen M, Wang Y. Compatibility art of traditional Chinese medicine: from the perspective of herb pairs. J Ethnopharmacol 2012; 143: 412-423
  CrossrefPubMedGoogle Scholar